XSTO
SCIB
Market cap14mUSD
, Last price
SEK
Name
SciBase Holding AB (publ)
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.
Key people
Non-Executive Chairman of the Board · since 2024
Chief Executive Officer · since 2023
Michael Colerus
Chief Financial Officer · since 2014
Angelica Korsfeldt
Director of Product Development · since 2023
Alf Laurell
Director of Quality Assurance and Regulatory Affairs · since 2022
Linn Olsen
Supply Chain and Production Manager · since 2020
Per Svedenhag
Head of Business Development and Marketing · since 2015
Anna Eriksrud
Independent Director · since 2025
Diana Ferro
Independent Director · since 2017
Robert Molander
Independent Director · since 2024
Thomas Taapken
Independent Director · since 2017
Headquarters & legal address
Box 3337
Stockholm, AB 103 67
SE
Stockholm, AB 103 67
SE
Previous name
SciBase Holding AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||